Mogamulizumab is a monoclonal antibody against CCR4 that was designed in Japan and licensed for the management of relapsed or refractory adult T cell leukemia/lymphoma in 2012 and elapsed/refractory CCR4+ cutaneous T cell lymphoma in 2014 [129]. This evidence concerns the gene CCR4 and lymphoma.